Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI)
Source: View publication →
In patients with STEMI and multivessel disease, FFR-guided staged complete revascularization during the index hospitalization significantly reduced the risk of major adverse cardiovascular events compared to culprit-lesion-only PCI, primarily driven by a decrease in repeat revascularization procedures.
Key Findings
Study Design
Study Limitations
Clinical Significance
This study established a robust evidence base for the safety and efficacy of physiology-guided complete revascularization in STEMI patients with multivessel disease, supporting a shift away from 'culprit-only' management toward a proactive, ischemia-guided complete revascularization approach during the index hospitalization to reduce future repeat procedures.
Historical Context
Prior to DANAMI-3-PRIMULTI and contemporary trials like PRAMI and CvLPRIT, the management of non-culprit vessels in STEMI was controversial, often defaulting to culprit-only PCI due to concerns that multi-vessel intervention might increase procedural risk or complications. These trials provided the necessary evidence to support updating international guidelines to recommend complete revascularization for this high-risk population.
Guided Discussion
High-yield insights from every perspective
What is the pathophysiological rationale for performing complete revascularization in a STEMI patient with multivessel disease, rather than simply treating the 'culprit' lesion that caused the heart attack?
Key Response
In STEMI, while the culprit lesion caused the acute event, the presence of non-culprit lesions in other vessels indicates a systemic pro-inflammatory and pro-thrombotic state. These non-culprit 'bystander' lesions can cause subsequent ischemia, arrhythmias, or future infarctions. DANAMI-3—PRIMULTI demonstrates that treating these lesions (staged during the index hospitalization) reduces future major adverse cardiovascular events (MACE), primarily by preventing the need for future urgent revascularizations.
Based on the DANAMI-3—PRIMULTI trial, what is the recommended timing for non-culprit lesion intervention, and how does this impact hospital resource management compared to previous 'culprit-only' strategies?
Key Response
The trial utilized a 'staged' approach, where non-culprit lesions were treated during the index hospitalization but after the primary PCI (median of 2 days later). This strategy suggests that complete revascularization does not need to be performed during the high-risk acute phase of the STEMI but should be completed before discharge. This requires coordination of catheterization lab schedules and potentially longer initial hospital stays but avoids the morbidity associated with future readmissions for ischemia-driven revascularization.
DANAMI-3—PRIMULTI utilized Fractional Flow Reserve (FFR) to guide non-culprit interventions. Discuss the physiological validity of using FFR in the acute/subacute STEMI setting, particularly regarding microvascular dysfunction.
Key Response
While FFR is the gold standard for stable CAD, there are concerns in STEMI that microvascular dysfunction (and associated blunted hyperemia) could lead to false-negative FFR readings (underestimating the severity of the stenosis). However, research suggests that microvascular resistance in the *non-culprit* territory remains relatively stable compared to the infarcted zone. DANAMI-3—PRIMULTI validated that using an FFR cutoff of ≤ 0.80 in non-culprit vessels is a clinically effective way to select lesions that benefit from PCI during the index hospitalization.
The primary endpoint reduction in DANAMI-3—PRIMULTI was driven almost entirely by 'ischemia-driven revascularization' rather than a reduction in death or recurrent MI. How should this affect your shared decision-making process with a patient who is hesitant about a second procedure?
Key Response
This highlights a nuance in STEMI care: complete revascularization improves 'quality of life' and reduces the 'burden of future procedures' rather than acting as a life-saving measure beyond the primary PCI. In shared decision-making, the attending should explain that while the second procedure (non-culprit PCI) carries its own small risks, it significantly lowers the 13% risk (seen in the culprit-only group) of needing an urgent, unplanned trip back to the hospital for a new procedure over the next two years.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Analyze the potential for 'ascertainment bias' in the DANAMI-3—PRIMULTI trial's primary endpoint and suggest a trial design modification that could have mitigated this risk.
Key Response
The trial was open-label, and the primary endpoint (MACE) included ischemia-driven revascularization. Because clinicians knew which patients had untreated non-culprit lesions, they may have been more likely to refer those patients for repeat PCI at the slightest sign of symptoms, compared to the 'complete' group. A more robust (though logistically difficult) design would be a double-blind, sham-controlled study where all patients undergo a second catheterization, but only the treatment group receives stents, ensuring that subsequent revascularization decisions are made by blinded clinicians.
As a reviewer, how would you critique the 'clinical significance' of the DANAMI-3—PRIMULTI results given that the study was underpowered for hard endpoints like cardiovascular mortality?
Key Response
An editor would flag that while the Hazard Ratio (0.56) is impressive, the composite endpoint is 'soft.' With only 2 deaths and 1 MI difference between the groups, the study fails to prove that non-culprit PCI saves lives. The editor would require the authors to emphasize that the benefit is strictly 'reduction in repeat revascularization' and ensure the abstract doesn't overstate the results as a reduction in 'hard' clinical events, which remained similar between groups.
How did DANAMI-3—PRIMULTI contribute to the evolution of ACC/AHA and ESC guidelines regarding the Class of Recommendation for non-culprit PCI in STEMI?
Key Response
Prior to 2013, non-culprit PCI during STEMI was often a Class III (Harm) recommendation unless the patient was in cardiogenic shock. DANAMI-3—PRIMULTI, alongside trials like PRAMI and CvLPRIT, provided the evidence needed to shift this to a Class IIa (Weak) and eventually a Class I (Strong) recommendation in the 2017 ESC and 2021 ACC/AHA guidelines. Specifically, it supported the 'staged' approach during the index admission, proving that a physiology-guided (FFR) approach is as valid as an angiography-guided approach used in other trials.
Clinical Landscape
Noteworthy Related Trials
PRAMI Trial
Tested
Preventive PCI of all significantly stenosed non-culprit arteries
Population
STEMI patients with multivessel disease
Comparator
Culprit-lesion-only PCI
Endpoint
Composite of cardiac death, nonfatal MI, or refractory angina
CvLPRIT Trial
Tested
Complete revascularization during the index admission
Population
Patients with STEMI and multivessel disease
Comparator
Culprit-only revascularization
Endpoint
Composite of all-cause mortality, MI, heart failure, and ischemia-driven revascularization at 12 months
COMPLETE Trial
Tested
Complete revascularization of non-culprit lesions
Population
Patients with STEMI and multivessel coronary artery disease
Comparator
Culprit-lesion-only PCI
Endpoint
Composite of cardiovascular death or MI
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis